An approval has been received from U.S. Food and Drug Administration (FDA) by APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ), for the marketing of Chlorothiazide Sodium for Injection, USP.
This injectable form of Chlorothiazide Sodium is expected to be launched by APP in the fourth quarter of 2009.
From News-Medical.Net:
Chlorothiazide Sodium for Injection, USP is therapeutically equivalent to the reference-listed drug Diuril®, which is marketed by Lundbeck Pharmaceuticals. According to 2008 IMS data, sales of this product in the United States were approximately $51 million1. Chlorothiazide is a diuretic used to treat high blood pressure (hypertension), as well as fluid retention in people with congestive heart failure, cirrhosis of the liver, kidney disorders, or edema caused by taking steroids or estrogen.
It was remarked by Thomas H. Silberg, president and chief executive officer of APP Pharmaceuticals, that the present stream of ANDA approvals reinforces APP's commitments in providing a consistently expanding portfolio of products to the customers and the patients.
Posts
No comments:
Post a Comment